Fig. 2From: Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study a Number of (i) Gd + lesions and (ii) new T2 lesions, and b proportion of patients free of (i) Gd + T1 and (ii) new T2 lesions in the core and extension studyBack to article page